| Revenue growth | 42% YoY in Q4 FY26; 15% for full year. |
|---|---|
| Margins | Margins maintained at 32.7% for FY26; synergy plan tracking ahead. |
| Demand visibility | Strong traction in Curatio and chronic business; US volumes increasing. |
| Management confidence | High comfort on organic expansion and Semaglutide market share. |
Growth
Q4 revenue grew 42%; base business ex-JB grew 16%. India business up 43%, US up 31% INR terms.
Outlook
Guided for mid-teens organic India growth; 20% of ₹450cr synergy target in Year 1; low single-digit Germany growth.
Risks
Geopolitical shocks impacting demand; price erosion/competition in Semaglutide; supply disruption from German third-party supplier.
Earnings Call filed with NSE, NSE: TORNTPHARM. Summary written with AI assistance from the document.
Torrent Pharmaceuticals Ltd: key numbers
- Share price
- ₹4,716.20
- Market cap
- ₹1,79,389 Cr
- Revenue (annual)
- ₹13,980 Cr
- Net profit (annual)
- ₹2,163 Cr
- P/E (TTM)
- 82.2×Sector 47.3×
- Promoter holding
- 60.78%-7.53% QoQ
- FII holding
- 17.97%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Torrent Pharmaceuticals Ltd
All →Torrent Pharmaceuticals Annual General Meeting
Shareholders approved the appointment of Ms. Shanti Ekambaram as an Independent Director of Torrent Pharmaceuticals via Postal Ballot.
Torrent Pharmaceuticals Other Announcement
Torrent Pharmaceuticals Limited has been assigned an ESG rating of 70 by NSE Sustainability Ratings and Analytics Limited. This independent assessment follows SEBI's regulatory framework for ESG Rating Providers.
Torrent Pharmaceuticals Annual General Meeting
Torrent Pharmaceuticals issued a Postal Ballot notice to shareholders for the appointment of Shanti Ekambaram as an Independent Director. Voting concludes on September 6, 2026.
Torrent Pharmaceuticals Earnings Call Transcript: Key Takeaways
Torrent Pharma delivered strong Q1 performance with revenues up 55% following the JB Chemicals merger completion. EBITDA margins jumped to 33.8% driven by accelerated cost synergies.
- Call
- Guides 10% growth
Torrent Pharmaceuticals Other Announcement
Torrent Pharmaceuticals submitted a statement under Regulation 52(7) & (7A) regarding the utilization of issue proceeds for the quarter ended June 30, 2026.
Torrent Pharmaceuticals Q1 FY27 Results: Net Profit ₹566 Cr, Up 3.3% YoY
Torrent Pharmaceuticals Ltd reported revenue from operations of ₹4,921 Cr (+54.8% YoY) and net profit of ₹566 Cr (+3.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹566 Cr · +3.3% YoY